Neuphoria Therapeutics (NEUP) Shares Outstanding (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Shares Outstanding (Entity) for 4 consecutive years, with $124.7 million the latest figure, recorded in Q3 2023.

• On a quarterly basis, Shares Outstanding (Entity) changed N/A year-over-year to $124.7 million in Q3 2023; TTM through Sep 2023 was $124.7 million, a N/A change from a year earlier, with the FY2023 full-year figure at $123.9 million, up 9.86% from the prior year.
• Shares Outstanding (Entity) was $124.7 million for Q3 2023 at Neuphoria Therapeutics, up from $123.9 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $124.7 million in Q3 2023 and troughed at $52.2 million in Q2 2020.
• A 4-year average of $95.7 million and a median of $112.8 million in 2022 frame the typical range for Shares Outstanding (Entity).
• Across the five-year window, Shares Outstanding (Entity) surged 73.52% in 2022 and advanced 9.86% in 2023, its largest moves.
• Over 4 years, Shares Outstanding (Entity) stood at $52.2 million in 2020, then gained by 24.55% to $65.0 million in 2021, then surged by 73.52% to $112.8 million in 2022, then gained by 10.54% to $124.7 million in 2023.
• The last three Shares Outstanding (Entity) figures came in at $124.7 million (Q3 2023), $123.9 million (Q2 2023), and $112.8 million (Q2 2022), per Business Quant data.